- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Biodesix, Inc.: Biodesix Recognized as a Top Workplace for Third Consecutive Year | 1 | GlobeNewswire (USA) | ||
| Mo | Biodesix, Inc.: Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development | 1 | GlobeNewswire (USA) | ||
| 20.03. | Biodesix Wobbles on News About Biomarker | 2 | Baystreet.ca | ||
| 20.03. | Biodesix publishes lung nodule biomarker validation study | 2 | Investing.com | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 20.03. | Biodesix veröffentlicht Validierungsstudie für Lungenrundherd-Biomarker | 2 | Investing.com Deutsch | ||
| 20.03. | Biodesix, Inc.: Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis | 350 | GlobeNewswire (Europe) | LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical... ► Artikel lesen | |
| 11.03. | Biodesix auf Barclays-Konferenz: Strategische Wachstumspläne in der Lungenkrebsdiagnostik | 1 | Investing.com Deutsch | ||
| 27.02. | William Blair upgrades Biodesix stock rating on execution momentum | 2 | Investing.com | ||
| 27.02. | William Blair stuft Biodesix hoch: Starke Geschäftsentwicklung überzeugt | 7 | Investing.com Deutsch | ||
| 27.02. | Biodesix, Inc. Q4 Loss Drops | - | RTTNews | ||
| 27.02. | Biodesix outlines $106M-$112M 2026 revenue target as sales expansion drives 41% Q4 growth | 2 | Seeking Alpha | ||
| 26.02. | Biodesix GAAP EPS of -$0.49 beats by $0.38, revenue of $28.7M beats by $2.45M | 1 | Seeking Alpha | ||
| 26.02. | Biodesix Earnings Report: Q4 Overview | 1 | Benzinga.com | ||
| 26.02. | BIODESIX INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Biodesix, Inc.: Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights | 245 | GlobeNewswire (Europe) | Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million,... ► Artikel lesen | |
| 26.02. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Biodesix, Inc.: Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 1 | GlobeNewswire (USA) | ||
| 06.02. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.01. | Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More | 4 | Insider Monkey | ||
| 13.01. | Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability | 4 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | EXKLUSIV zu Valneva: Analysten sehen massives Kurspotenzial - Die Chance die sich zum Wochenstart ergibt | ||
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| NANOREPRO | 1,455 | +2,83 % | NanoRepro: Wichtige strategische Schritte | Vermutlich ist der Schritt überfällig - in der operativen Hektik des Tagesgeschäfts bislang aber untergegangen. Die im Geschäft mit medizinischen Schnelltests beheimatete NanoRepro AG will für ihr in... ► Artikel lesen | |
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,443 | -6,24 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INFLARX | 0,841 | -1,87 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| INTELLIA THERAPEUTICS | 11,400 | -1,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 36,640 | +0,07 % | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| GENMAB | 238,20 | -0,46 % | Passing of Genmab A/S' Annual General Meeting | Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,350 | -1,46 % | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon),... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,160 | +0,02 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen |
Das Unternehmen BIODESIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,100 (-0,76 %) liegt der Kurs bei 13,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.